Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31703956 | 0.86 | TSHR (0.60) | TSHRMAPTPKM | |
| SCHEMBL31703528 | 0.79 | MAPT (0.43) | MAPT | |
| SCHEMBL2189830 | 0.79 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189838 | 0.79 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189833 | 0.79 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL31703463 | 0.78 | MAPT (0.42) | TSHRMAPTPKM | |
| SCHEMBL31703439 | 0.78 | SLC6A4 (0.40) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2188612 | 0.76 | MAPT (0.45) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189606 | 0.76 | MAPT (0.45) | SLC6A4SLC6A3SLC6A2MAPTPKM | |
| SCHEMBL2189600 | 0.76 | MAPT (0.45) | SLC6A4SLC6A3SLC6A2MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215536-A1 | MACROCYCLIC PANRAS INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |